Seek Returns logo

LLY vs. WFC: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at LLY and WFC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolLLYWFC
Company NameEli Lilly and CompanyWells Fargo & Company
CountryUnited StatesUnited States
GICS SectorHealth CareFinancials
GICS IndustryPharmaceuticalsBanks
Market Capitalization739.95 billion USD272.32 billion USD
ExchangeNYSENYSE
Listing DateJune 1, 1972June 1, 1972
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of LLY and WFC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

LLY vs. WFC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolLLYWFC
5-Day Price Return2.85%-4.09%
13-Week Price Return-2.12%-0.76%
26-Week Price Return-7.71%11.88%
52-Week Price Return-13.08%43.16%
Month-to-Date Return4.15%-3.52%
Year-to-Date Return-1.17%15.13%
10-Day Avg. Volume4.02M14.36M
3-Month Avg. Volume4.14M15.91M
3-Month Volatility41.96%24.42%
Beta0.411.14

Profitability

Return on Equity (TTM)

LLY

88.36%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.85%
Q1
5.40%
Min
-10.91%

LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

WFC

11.36%

Banks Industry

Max
25.40%
Q3
15.55%
Median
12.00%
Q1
8.98%
Min
-0.10%

WFC’s Return on Equity of 11.36% is on par with the norm for the Banks industry, indicating its profitability relative to shareholder equity is typical for the sector.

LLY vs. WFC: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Net Profit Margin (TTM)

LLY

25.91%

Pharmaceuticals Industry

Max
40.67%
Q3
19.07%
Median
12.31%
Q1
4.50%
Min
-9.91%

A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

WFC

22.19%

Banks Industry

Max
54.20%
Q3
35.73%
Median
28.97%
Q1
22.56%
Min
6.98%

Falling into the lower quartile for the Banks industry, WFC’s Net Profit Margin of 22.19% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

LLY vs. WFC: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Operating Profit Margin (TTM)

LLY

32.37%

Pharmaceuticals Industry

Max
45.78%
Q3
23.14%
Median
16.68%
Q1
7.98%
Min
-7.13%

An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

WFC

25.35%

Banks Industry

Max
63.35%
Q3
44.73%
Median
37.24%
Q1
28.25%
Min
12.28%

WFC’s Operating Profit Margin of 25.35% is in the lower quartile for the Banks industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

LLY vs. WFC: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Profitability at a Glance

SymbolLLYWFC
Return on Equity (TTM)88.36%11.36%
Return on Assets (TTM)16.02%1.06%
Net Profit Margin (TTM)25.91%22.19%
Operating Profit Margin (TTM)32.37%25.35%
Gross Profit Margin (TTM)82.64%--

Financial Strength

Current Ratio (MRQ)

LLY

1.28

Pharmaceuticals Industry

Max
4.65
Q3
2.64
Median
1.85
Q1
1.26
Min
0.78

LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

WFC

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

For the Banks industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

LLY vs. WFC: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Banks industry benchmarks.

Debt-to-Equity Ratio (MRQ)

LLY

2.18

Pharmaceuticals Industry

Max
1.75
Q3
0.82
Median
0.35
Q1
0.13
Min
0.00

With a Debt-to-Equity Ratio of 2.18, LLY operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

WFC

2.01

Banks Industry

Max
5.78
Q3
2.66
Median
1.05
Q1
0.40
Min
0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Banks industry.

LLY vs. WFC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Banks industry benchmarks.

Interest Coverage Ratio (TTM)

LLY

20.36

Pharmaceuticals Industry

Max
103.95
Q3
43.60
Median
9.83
Q1
2.37
Min
-42.71

LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

WFC

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Banks industry.

LLY vs. WFC: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Financial Strength at a Glance

SymbolLLYWFC
Current Ratio (MRQ)1.28--
Quick Ratio (MRQ)0.53--
Debt-to-Equity Ratio (MRQ)2.182.01
Interest Coverage Ratio (TTM)20.36--

Growth

Revenue Growth

LLY vs. WFC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

LLY vs. WFC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

LLY

0.68%

Pharmaceuticals Industry

Max
7.14%
Q3
3.45%
Median
2.17%
Q1
0.33%
Min
0.00%

LLY’s Dividend Yield of 0.68% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

WFC

2.41%

Banks Industry

Max
11.03%
Q3
6.00%
Median
3.87%
Q1
2.41%
Min
0.00%

WFC’s Dividend Yield of 2.41% is consistent with its peers in the Banks industry, providing a dividend return that is standard for its sector.

LLY vs. WFC: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Dividend Payout Ratio (TTM)

LLY

36.46%

Pharmaceuticals Industry

Max
199.58%
Q3
97.17%
Median
53.47%
Q1
22.97%
Min
0.00%

LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

WFC

31.00%

Banks Industry

Max
134.24%
Q3
79.39%
Median
55.09%
Q1
36.09%
Min
0.00%

WFC’s Dividend Payout Ratio of 31.00% is in the lower quartile for the Banks industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.

LLY vs. WFC: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Dividend at a Glance

SymbolLLYWFC
Dividend Yield (TTM)0.68%2.41%
Dividend Payout Ratio (TTM)36.46%31.00%

Valuation

Price-to-Earnings Ratio (TTM)

LLY

53.86

Pharmaceuticals Industry

Max
45.19
Q3
27.91
Median
20.59
Q1
15.08
Min
3.79

At 53.86, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

WFC

12.84

Banks Industry

Max
22.69
Q3
13.75
Median
10.32
Q1
7.73
Min
2.59

WFC’s P/E Ratio of 12.84 is within the middle range for the Banks industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

LLY vs. WFC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Price-to-Sales Ratio (TTM)

LLY

13.96

Pharmaceuticals Industry

Max
8.87
Q3
4.56
Median
2.14
Q1
1.58
Min
0.11

With a P/S Ratio of 13.96, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

WFC

1.91

Banks Industry

Max
4.90
Q3
2.98
Median
2.24
Q1
1.59
Min
0.45

The P/S Ratio is often not a primary valuation tool in the Banks industry.

LLY vs. WFC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Price-to-Book Ratio (MRQ)

LLY

40.43

Pharmaceuticals Industry

Max
9.78
Q3
4.99
Median
2.48
Q1
1.53
Min
0.59

At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

WFC

1.42

Banks Industry

Max
2.09
Q3
1.40
Median
1.11
Q1
0.86
Min
0.29

WFC’s P/B Ratio of 1.42 is in the upper tier for the Banks industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

LLY vs. WFC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Banks industry benchmarks.

Valuation at a Glance

SymbolLLYWFC
Price-to-Earnings Ratio (TTM)53.8612.84
Price-to-Sales Ratio (TTM)13.961.91
Price-to-Book Ratio (MRQ)40.431.42
Price-to-Free Cash Flow Ratio (TTM)369.8717.44